TRIM29-dependent AKR1B10 degradation ameliorates MASH
Science Advances · 2026
DOI: 10.1126/sciadv.aeb9309 ↗At a glance
Journal article in Science Advances, 2026. Written by Zhengcai Ma and 17 co-authors. Institution: Engineering Research Center of Coptis Development and Utilization (Ministry of Education), School of Life Sciences, Southwest University, Chongqing 4…. Major MEDLINE topics: Transcription Factors, DNA-Binding Proteins, Aldo-Keto Reductases. Cited 1 times so far (Crossref); 59 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, National key R&D program of China.
Abstract (original language)
Metabolic dysfunction–associated steatohepatitis (MASH) is a prevalent and life-threatening liver disease with limited effective therapies, necessitating the urgent identification of previously unidentified molecular targets and effective pharmacologic agents. This study identifies aldo-keto reductase family 1 member B10 (AKR1B10) as the MASH hallmark, showing elevated expression in patient tissues and serum, correlating strongly with disease severity. Genetic ablation of Akr1b10 in mice significantly attenuated high-fat/high-cholesterol (HFHC) diet–induced steatosis, inflammation, and fibrosis. Mechanistically, we found that tripartite motif protein 29 (TRIM29) functions as an E3 ubiquitin ligase that directly binds AKR1B10, promoting its ubiquitination and proteasomal degradation, which ameliorates MASH progressions. Furthermore, the natural compound coptisine (COP) allosterically facilitated TRIM29-AKR1B10 interaction, accelerating AKR1B10 degradation and showing improved efficacy in MASH mice. Moreover, Trim29 overexpression enhances COP-mediated symptoms alleviation. Our findings delineate the TRIM29/AKR1B10 axis as a druggable signaling pathway and identify COP as a promising therapeutic candidate for MASH.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Engineering Research Center of Coptis Development and Utilization (Ministry of Education), School of Life Sciences, Southwest University, Chongqing 400715, China.
- Faculty of Chemistry and Life Sciences, Gansu Minzu Normal University, Gansu 747000, China.
- Engineering Research Center of Coptis Development and Utilization (Ministry of Education), College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China.
- Chengdu University of Traditional Chinese Medicine, No. 1166 Liutai Avenue, Wenjiang District, Chengdu 611137, Sichuan Province, China.
- Department of Clinical Laboratory, AnShun City People's Hospital, Guizhou 561000, China.
- Department of Pathology, Chongqing University Three Gorges Hospital, Chongqing University, Wanzhou 404100, Chongqing, China.
ORCID profiles: Zhengcai Ma, Juan Li, Xiaoduo Li, Jianyu Zhu, Chunyong Sun, Jinyin Zhang, Zhipeng Yang, Jifei Liu, Yuan Zhou, Zhenwei Gui, Jingwei Li, Hongmei Wang, Dan Shi, Qiang Song, Xuegang Li, Rongkun Tao, Hang Ma, Xiaoli Ye
Funding
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- National key R&D program of China
- Special Fund for Youth Team of Southwest University
- the Key Project at the central government level: the ability establishment of sustainable use for valuable Chinese medicine resources
- Chongqing Bayu Qihuang scholars support project
- Program of Traditional Chinese Medicine innovation team construction of Chongqing
- Special Key project of Technology Innovation and Application Development from Chongqing
Cite
APA
Ma, Z., Li, J., Li, X., Zhu, J., Sun, C., Zhang, J., Yang, Z., Liu, J., Zhou, Y., Gui, Z., Li, J., Wang, H., Shi, D., Song, Q., Li, X., Tao, R., Ma, H., & Ye, X. (2026). TRIM29-dependent AKR1B10 degradation ameliorates MASH. Science Advances. https://doi.org/10.1126/sciadv.aeb9309
Vancouver
Ma Z, Li J, Li X, Zhu J, Sun C, Zhang J, et al. TRIM29-dependent AKR1B10 degradation ameliorates MASH. Science Advances. 2026. doi:10.1126/sciadv.aeb9309
BibTeX
@article{Ma2026,
author = {Ma, Zhengcai and Li, Juan and Li, Xiaoduo and Zhu, Jianyu and Sun, Chunyong and Zhang, Jinyin and Yang, Zhipeng and Liu, Jifei and Zhou, Yuan and Gui, Zhenwei and Li, Jingwei and Wang, Hongmei and Shi, Dan and Song, Qiang and Li, Xuegang and Tao, Rongkun and Ma, Hang and Ye, Xiaoli},
title = {TRIM29-dependent AKR1B10 degradation ameliorates MASH},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aeb9309}
}
EUVIMED